Consistently, SPOP inhibition synergized with anti–PD-1 therapy to suppress tumor growth via enhanced CD4+IFN-γ+ T cell infiltration and further boosted CAR.CD19-T efficacy in B16-OVA tumors. Here, CD4 is linked to neoplasm.